Colorectal cancer is one of the most common malignancies in man, and environmental as well as hereditary factors are involved in the carcinogenic process. A small subset of colorectal cancers (<1%) develops in patients with one of the polyposis coli syndromes: familial adenomatous polyposis (FAP), Gardner's syndrome, and Turcot's syndrome (Lynch et al., 1991 ).
Turcot's syndrome, the association of intestinal polyposis with neuroepithelial brain tumours such as glioma, glioblastoma and medulloblastoma, was first described by Crail in 1949 (Crail, 1949) , and later by Turcot et al. (1959) . So far, some 30 cases have been reported in the literature, but there is no information on molecular alterations involved in the development and progression of the disease.
Sporadic mutations in the p53 tumour suppressor gene are the most common genetic alterations observed in human malignancies (Levine et al., 1991) , and occur in approximately 70% of colorectal cancers (Hollstein et al., 1991) . Recently, germline mutations of the p53 gene have been described in patients with Li-Fraumeni syndrome and other hereditary forms of cancer (Malkin et al., 1990 (Malkin et al., , 1992 Srivasta et al., 1990; Toguchida et al., 1992) .
To determine the role of p53 and other oncogenes and tumour suppressor genes in Turcot's syndrome, we studied tissues derived from a 15-year-old patient with polyposis coli, metastasising colorectal cancer, and malignant astrocytoma as well as from her parents. Material from the hemicolectomy was available as paraffin embedded block only. Tissues from the hemihepatectomy, the craniotomy, and the skin-metastasectomy were frozen with liquid nitrogen and stored at -80°C. Figure 1 shows representative photomicrographs of the benign and malignant tissues that were used for immunohistochemical and molecular evaluation in this study.
Materials and methods
Ras mutation analysis PCR-amplified fragments of the Ki-ras gene were probed on slot-blots with labelled mutation-specific oligomers as described previously (Rochlitz et al., 1989) .
VNTR-amplification
To detect loss of heterozygozity (LOH) on chromosome 17p, we used PCR-directed amplification of a VNTR region on the pYNZ22 locus as described by Horn et al. (1989) .
Sequencing ofp53
Exons 4-9 of the p53 gene were PCR-amplified and sequenced as described (Baker et al., 1989) .
APAAP
Immunohistochemical staining of the p53 protein was performed using the murine monoclonal antibody PAbl 801 (Dianova, Hamburg, Germany) as described (Cordell et al., 1984) .
Differential PCR
To measure the expression of the p53 gene we used differential PCR as described by others and ourselves (Frye et al., 1989; Neubauer et al., 1990; Noonan et al., 1990) .
Results
The lymph node, the skin and the liver metastasis of the patient's colon carcinoma carried a glycine to alanine mutation in codon 12 of the Ki-ras gene, while the primary colon carcinoma as well as the astrocytoma and all the normal tissues harboured only the wild type allele of the Ki-ras gene (Figure 2 (Figure 4 ) and an arginine to histidine mutation in codon 273 in the astrocytoma. There was no mutation of the p53 gene in the lymphocytes of the patient or her parents.
Immunocytochemistry confirmed the results of p53 sequencing: intense nuclear staining with the anti-p53 antibody PAbl801 was observed in the skin and the liver metastasis of the CRC whereas the astrocytoma showed weak cytoplasmic staining. By use of differential PCR the p53 mRNA expression (relative to normal colonic mucosa) of the liver metastasis, the skin metastasis, and the astrocytoma were determined to be 1.5, 2.4 and 1.8, respectively (data not shown).
Discussion
The case presented here are that of a 15-year-old girl with polyposis coli, colonic carcinoma metastasising to lymph nodes, the liver and the skin, and a high grade astrocytoma, representing a Turcot's syndrome, type III in the Lewis classification system (Lewis et al., 1983) .
In the molecular analysis of this patient's tumours we focused our attention to chromosome 17p and the p53 tumour suppressor gene for two reasons: first, p53 is the most frequently altered gene in both colorectal cancer and brain tumours (Vogelstein et al., 1988; Hollstein et al., 1991; von Deimling et al., 1992) . Second, p53 is one of the genes that may predispose to the development of cancer, and reports on p53 germline mutations in several hereditary cancer syndromes have been published recently (Malkin et al., 1990 (Malkin et al., , 1992 Srivasta et al., 1990; Santibanez-Koref et al., 1991; Toguchida et al., 1992) .
Our findings of a codon 175 point mutation of the p53 gene in the skin and the liver metastasis of a sigmoid carcinoma and of a codon 273 mutation in the astrocytoma of our patient demonstrate that the p53 gene played a role in the carcinogenic process. In addition, deletions on chromosome 17p, the location of the p53 gene, were present in both the skin and the liver metastasis of the sigmoid carcinoma but not in the astrocytoma. Similarly, increased protein and mRNA expression of p53 was shown in all the malignant tissues of the patient. Lymphocytes from the patient and her parents were also evaluated for p53 mutations but found to contain solely the wild type sequence of the gene. This argues strongly against a role of p53 as a cancer predisposition gene in this case of Turcot's syndrome.
Alterations of other genes involved in tumour development and progression were also examined. The fact that a Ki-ras mutation was detected in three different metastases of the sigmoid carcinoma but not in a colonic adenoma, the sigmoid primary tumour or in the astrocytoma, suggests that this ras mutation might have occurred in a single cell, late in the development of the primary colon cancer, enabling this cell to metastasise to different sites.
In addition, overexpression of the c-myc oncogene, the nm23 'metastasis suppressor gene', and of the MDRl gene was detected in some of the malignant tissues (data not shown) and underlines that the same genetic events that drive the carcinogenic process in diverse human sporadic malignancies were involved in this rare hereditary disease.
Germline alterations different from those analysed in this study must be responsible for the predisposition to malignancy in this individual patient. In the light of the well 
